Publication of exalt-1 trial in cancer discovery demonstrates first ai-supported functional precision medicine platform to improve cancer treatment outcomes

Vienna & oxford, england--(business wire)--exscientia (nasdaq: exai), the medical university of vienna and the cemm research center for molecular medicine of the austrian academy of sciences, today announced publication in cancer discovery, a journal of the american association of cancer research, of final results from the exalt-1 trial. the study, titled “functional precision medicine provides clinical benefit in advanced aggressive haematological cancers and identifies exceptional responders,
EXAI Ratings Summary
EXAI Quant Ranking